Advancing Therapy in Type 2 Diabetes | Pharmacy QI | July 2021

July 2021 | Practical Tips for Quality Improvement | View PDF

Regular Review

  1. Assess glycemic control, cardiovascular and renal status
  2. Screen for complications (eyes, feet, kidneys)
  3. Review efficacy, side effects and ability to take medications
  4. Reinforce and support healthy behaviour interventions

*CV Risk Factors: tobacco use, dyslipidemia, hypertension
MACE: Major Adverse CV Event, HHF: Hospitalization for Heart Failure
Adapted from: Lipscome L, Butalia S, Dasgupta K, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Figure 2A. http://guidelines.diabetes.ca/cpg/chapter-13-2020-update. Accessed May 27, 2021.


Reference:

  1. Lipscome L, Butalia S, Dasgupta K, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. http://guidelines.diabetes.ca/cpg/chapter-13-2020-update. Accessed May 27, 2021.
  2. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes
    2018;42(Suppl 1):S1-S325.
  3. Government of Canada. Drug Product Database. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Accessed May 27, 2021.

Sign up for our Newsletter

Get updates delivered to your inbox